Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 19.22 Million AUD | -29.63% |
| 2023 | 27.31 Million AUD | -33.96% |
| 2022 | 41.36 Million AUD | 23.16% |
| 2021 | 33.58 Million AUD | 152.43% |
| 2020 | 13.3 Million AUD | -33.17% |
| 2019 | 19.9 Million AUD | 6.32% |
| 2018 | 18.72 Million AUD | -25.93% |
| 2017 | 25.28 Million AUD | -25.04% |
| 2016 | 33.72 Million AUD | -19.38% |
| 2015 | 41.83 Million AUD | 0.46% |
| 2014 | 41.64 Million AUD | 143.89% |
| 2013 | 17.07 Million AUD | 132.55% |
| 2012 | 7.34 Million AUD | -18.52% |
| 2011 | 9.01 Million AUD | 32.49% |
| 2010 | 6.8 Million AUD | 47.95% |
| 2009 | 4.59 Million AUD | -60.79% |
| 2008 | 11.72 Million AUD | 51.85% |
| 2007 | 7.72 Million AUD | -25.96% |
| 2006 | 10.42 Million AUD | -53.03% |
| 2005 | 22.19 Million AUD | -46.07% |
| 2004 | 41.16 Million AUD | 151.9% |
| 2003 | 16.34 Million AUD | -7.1% |
| 2002 | 17.59 Million AUD | -21.07% |
| 2001 | 22.28 Million AUD | 6.76% |
| 2000 | 20.87 Million AUD | 1036.48% |
| 1999 | 1.83 Million AUD | 821.77% |
| 1998 | 199.28 Thousand AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 22.19 Million AUD | -18.76% |
| 2024 Q4 | 19.22 Million AUD | 0.0% |
| 2024 Q3 | 19.22 Million AUD | -13.38% |
| 2024 FY | 19.22 Million AUD | -29.63% |
| 2024 Q2 | 22.19 Million AUD | 0.0% |
| 2023 Q3 | 27.31 Million AUD | -18.17% |
| 2023 Q4 | 27.31 Million AUD | 0.0% |
| 2023 FY | 27.31 Million AUD | -33.96% |
| 2023 Q2 | 33.38 Million AUD | 0.0% |
| 2023 Q1 | 33.38 Million AUD | -19.29% |
| 2022 Q1 | 44.93 Million AUD | 33.78% |
| 2022 Q4 | 41.36 Million AUD | 0.0% |
| 2022 FY | 41.36 Million AUD | 23.16% |
| 2022 Q2 | 44.93 Million AUD | 0.0% |
| 2022 Q3 | 41.36 Million AUD | -7.94% |
| 2021 Q1 | 37.4 Million AUD | 181.15% |
| 2021 Q3 | 33.58 Million AUD | -10.21% |
| 2021 FY | 33.58 Million AUD | 152.43% |
| 2021 Q2 | 37.4 Million AUD | 0.0% |
| 2021 Q4 | 33.58 Million AUD | 0.0% |
| 2020 Q2 | 14.48 Million AUD | 0.0% |
| 2020 Q1 | 14.48 Million AUD | -27.24% |
| 2020 Q3 | 9.9 Million AUD | -31.6% |
| 2020 Q4 | 13.3 Million AUD | 34.29% |
| 2020 FY | 13.3 Million AUD | -33.17% |
| 2019 Q3 | 19.9 Million AUD | 40.75% |
| 2019 FY | 19.9 Million AUD | 6.32% |
| 2019 Q4 | 19.9 Million AUD | 0.0% |
| 2019 Q1 | 14.14 Million AUD | -24.46% |
| 2019 Q2 | 14.14 Million AUD | 0.0% |
| 2018 FY | 18.72 Million AUD | -25.93% |
| 2018 Q4 | 18.72 Million AUD | 0.0% |
| 2018 Q3 | 18.72 Million AUD | -14.61% |
| 2018 Q2 | 21.93 Million AUD | 0.0% |
| 2018 Q1 | 21.93 Million AUD | -13.25% |
| 2017 Q1 | 30.41 Million AUD | -9.83% |
| 2017 FY | 25.28 Million AUD | -25.04% |
| 2017 Q4 | 25.28 Million AUD | 0.0% |
| 2017 Q3 | 25.28 Million AUD | -16.87% |
| 2017 Q2 | 30.41 Million AUD | 0.0% |
| 2016 FY | 33.72 Million AUD | -19.38% |
| 2016 Q4 | 33.72 Million AUD | 0.0% |
| 2016 Q2 | 38.59 Million AUD | 0.0% |
| 2016 Q1 | 38.59 Million AUD | -7.75% |
| 2016 Q3 | 33.72 Million AUD | -12.61% |
| 2015 Q2 | 39.8 Million AUD | 0.0% |
| 2015 FY | 41.83 Million AUD | 0.46% |
| 2015 Q1 | 39.8 Million AUD | -4.41% |
| 2015 Q3 | 41.83 Million AUD | 5.1% |
| 2015 Q4 | 41.83 Million AUD | 0.0% |
| 2014 Q1 | 24.52 Million AUD | 43.63% |
| 2014 FY | 41.64 Million AUD | 143.89% |
| 2014 Q4 | 41.64 Million AUD | 0.0% |
| 2014 Q3 | 41.64 Million AUD | 69.8% |
| 2014 Q2 | 24.52 Million AUD | 0.0% |
| 2013 Q4 | 17.07 Million AUD | 0.0% |
| 2013 FY | 17.07 Million AUD | 132.55% |
| 2013 Q3 | 17.07 Million AUD | 33.27% |
| 2013 Q2 | 12.81 Million AUD | 0.0% |
| 2012 Q2 | 7.58 Million AUD | 0.0% |
| 2012 Q4 | 7.34 Million AUD | 0.0% |
| 2012 FY | 7.34 Million AUD | -18.52% |
| 2011 FY | 9.01 Million AUD | 32.49% |
| 2011 Q4 | 9.01 Million AUD | 0.0% |
| 2011 Q2 | 3.65 Million AUD | 0.0% |
| 2010 FY | 6.8 Million AUD | 47.95% |
| 2010 Q4 | 6.8 Million AUD | 0.0% |
| 2010 Q2 | 8.61 Million AUD | 0.0% |
| 2009 Q2 | 8.3 Million AUD | 0.0% |
| 2009 FY | 4.59 Million AUD | -60.79% |
| 2009 Q4 | 4.59 Million AUD | 0.0% |
| 2008 Q4 | 11.72 Million AUD | 0.0% |
| 2008 Q2 | 9.82 Million AUD | 0.0% |
| 2008 FY | 11.72 Million AUD | 51.85% |
| 2007 Q4 | 7.72 Million AUD | 0.0% |
| 2007 FY | 7.72 Million AUD | -25.96% |
| 2007 Q2 | 11.98 Million AUD | 0.0% |
| 2006 Q2 | 16.24 Million AUD | 0.0% |
| 2006 Q4 | 10.42 Million AUD | 0.0% |
| 2006 FY | 10.42 Million AUD | -53.03% |
| 2005 Q4 | 22.19 Million AUD | 0.0% |
| 2005 FY | 22.19 Million AUD | -46.07% |
| 2005 Q2 | 38.85 Million AUD | 0.0% |
| 2004 Q4 | 41.16 Million AUD | 0.0% |
| 2004 Q2 | 18.25 Million AUD | 0.0% |
| 2004 FY | 41.16 Million AUD | 151.9% |
| 2003 Q4 | 16.34 Million AUD | 0.0% |
| 2003 Q2 | 14.88 Million AUD | 0.0% |
| 2003 FY | 16.34 Million AUD | -7.1% |
| 2002 FY | 17.59 Million AUD | -21.07% |
| 2001 FY | 22.28 Million AUD | 6.76% |
| 2000 FY | 20.87 Million AUD | 1036.48% |
| 1999 FY | 1.83 Million AUD | 821.77% |
| 1998 FY | 199.28 Thousand AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | 7.037% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 184.00 USD | -10447586.413% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -599.978% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3752.152% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 50.514% |
| Kadimastem Ltd | 2.3 Million USD | -734.335% |
| Zenith Capital Corp. | 7410.00 USD | -259329.73% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -13345.81% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 35.953% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -25077.126% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4930.063% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 85.236% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -26464.973% |
| Qrons Inc. | 420.00 USD | -4576981.667% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -84284.983% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -5873.706% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1945.756% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -4352.888% |
| Affymax, Inc. | 7.44 Million USD | -158.279% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 95.693% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -881.71% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -363.667% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -832096.667% |
| Biomind Labs Inc. | 73.81 Thousand USD | -25941.728% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 63.523% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -7257.61% |
| CytoDyn Inc. | 11.13 Million USD | -72.627% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -82.147% |
| IMV Inc. | 31.33 Million USD | 38.649% |
| Genus plc | 1.02 Billion USD | 98.132% |
| Halberd Corporation | 10.13 Thousand USD | -189651.683% |
| Helix BioMedix, Inc. | 3.02 Million USD | -535.478% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -166.266% |
| LadRx Corporation | 2.3 Million USD | -732.96% |
| Marizyme, Inc. | 22.01 Million USD | 12.679% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -107415.341% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 45.354% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -4824.543% |
| Q BioMed Inc. | 3.51 Million USD | -446.825% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5336.318% |
| Enzolytics Inc. | 361.7 Million USD | 94.685% |
| CSL Limited | 38.02 Billion USD | 99.949% |
| Skye Bioscience, Inc. | 11.94 Million USD | -60.997% |
| SQZ Biotechnologies Company | 107.18 Million USD | 82.065% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -480.25% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1315.224% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -7255.161% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2905.325% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 59.7% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2965.988% |
| NovAccess Global Inc. | 62.24 Thousand USD | -30782.507% |
| HST Global, Inc. | 1526.00 USD | -1259647.248% |
| SYBLEU INC | 330.46 Thousand USD | -5717.127% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 85.041% |
| Alpha Cognition Inc. | 2.45 Million USD | -683.948% |
| AVAX Technologies, Inc. | 7.37 Million USD | -160.585% |
| Mesoblast Limited | 667.9 Million USD | 97.122% |
| MultiCell Technologies, Inc. | 126.22 USD | -15230246.221% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1242.41% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2696.238% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2394.504% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 95.847% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -638.467% |
| GB Sciences, Inc. | 103.44 Thousand USD | -18484.079% |
| argenx SE | 4.54 Billion USD | 99.577% |
| Resverlogix Corp. | 8.11 Million USD | -136.891% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -923.694% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 31.206% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1226.834% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -114.811% |
| ONE Bio Corp. | 70.08 Million USD | 72.571% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.432% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1971.611% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1845.788% |
| Agentix Corp. | 261.39 Thousand USD | -7254.373% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -32.029% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -33570.338% |
| Cell Source, Inc. | 195.17 Thousand USD | -9749.692% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3900.304% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5336.318% |
| Itoco Inc. | 1.4 Million USD | -1273.054% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -19996.536% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -18035.607% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4887.079% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -3381.805% |
| Rebus Holdings, Inc. | 5000.00 USD | -384374.86% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -4595.337% |
| Mobile Lads Corp. | 52.00 USD | -36968636.538% |
| International Stem Cell Corporation | 5.39 Million USD | -256.656% |
| Bioxytran, Inc. | 137.63 Thousand USD | -13866.886% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -28.143% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -15.952% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -24233.852% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2123.228% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -155.737% |
| Neutra Corp. | 2851.00 USD | -674180.709% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 40.678% |
| PureTech Health plc | 693.97 Million USD | 97.23% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -138.18% |
| IXICO plc | 15.84 Million USD | -21.332% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -132.115% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 81.395% |
| CSL Limited | 38.02 Billion USD | 99.949% |
| Cellectis S.A. | 333.99 Million USD | 94.244% |